Phase 3 Dyspnoea Clinical Trials
6 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–6 of 6 trials
Terminated
Phase 3
Opioids for breathlessness in people with mesothelioma or asbestosis or other causes of interstitial lung disease.
Dyspnoea in opioid naive participants with mesothelioma or asbestosis or other causes of interstitial lung disease.
Flinders University - Department of Palliative and Support Services144 enrolled3 locationsACTRN12611000711910
Completed
Phase 3
Efficacy of sertraline for palliative management of refractory breathlessness
Intractable dyspnoea
Flinders University150 enrolled10 locationsACTRN12610000464066
Terminated
Phase 3
Midazolam Nasal Spray for the treatment of breathlessness in patients with life-limiting disease
Dyspnoea (Breathlessness)
Arohanui Hospice Service Trust, Clare Randall as representative200 enrolled3 locationsACTRN12609000506291
Recruiting
Phase 3
Opioids for breathlessness in people with primary hypertension.
Dyspnoea in opioid naive participants with primary pulmonary hypertension.
Flinders University - Department of Palliative and Support Services40 enrolled1 locationACTRN12609000209291
Completed
Phase 3
A prospective, randomized, placebo-controlled, double-blind, cross-over study of the usefulness of sustained-release opioids in the subjective sensation of dyspnoea secondary to advanced disease with no reversible components in opioid naive patients.
Opioids in Refractory dyspnoea
Repatriation General Hospital48 enrolled1 locationACTRN12607000075482
Not Yet Recruiting
Phase 3Phase 4
The use of opioids to relieve dysponea in the palliative care setting.
Dyspnoea
Repatriation General Hospital100 enrolled1 locationACTRN12606000269538